Diabetic eye disease refers to a group of eye problems that people with diabetes may face as a complication of diabetes. All can cause severe vision loss or even blindness. Diabetic eye disease may include, diabetic retinopathy — damage to the blood vessels in the retina, Cataract—clouding of the eye's lens, glaucoma—increase in fluid pressure inside the eye that leads to optic nerve damage and loss of vision. A person with diabetes is nearly twice as likely to get glaucoma as other adults.
David Watson has worn glasses to correct nearsightedness the majority of his life, and had his vision checked regularly to make sure his prescription was up to date. But when his wife convinced him to have a comprehensive dilated eye exam, he got a surprise. His doctor told him something didn't look right with his retina, the light sensitive tissue at the back of his eye. His retina was torn, and he had not had any symptoms.
ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR).
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be highly effective for treating proliferative diabetic retinopathy, an eye disease that can occur as a complication of diabetes.
A new study has found that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later.
For decades, clinicians have detected and monitored diabetic eye disease with standard retinal photographs that cover about a third of the retina. In recent years, an emerging class of ultrawide field (UWF) cameras has given a substantially larger view of the retina, providing new insight on the presentation and natural history of retinal disease.
Placebo-controlled trial findings show that lipoprotein-associated phospholipase A2 inhibition modestly benefits the vision of patients with centre-involved diabetic macular oedema and warrants further investigation.
New York Eye and Ear Infirmary of Mount Sinai joins with the International Orthoptic Association to observe June 1st as World Orthoptics Day.
Reporting on their study with lab-grown human cells, researchers at The Johns Hopkins University and the University of Maryland say that blocking a second blood vessel growth protein, along with one that is already well-known, could offer a new way to treat and prevent a blinding eye disease caused by diabetes.
Research published today in the Proceedings of the National Academy of Sciences demonstrates that technology invented by researchers at Oregon Health & Science University's Casey Eye Institute can improve the clinical management of the leading causes of blindness.
An ophthalmology research team at the University of Wisconsin-Madison took part in a nationwide clinical trial comparing treatments for a form of diabetic eye disease. The study found that three commonly used drugs perform much the same for those with mild vision problems, but one medication performed better for those with more serious vision loss.
Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute.
In one of the first studies of its kind, researchers found that the prevalence of geriatric conditions and diabetic complications among older, insured patients with diabetes did not vary significantly by ethnicity.
The team behind Peek, the Portable Eye Examination Kit, are calling on the public to help provide a solution to avoidable blindness by increasing access to potentially life-changing new eye health testing equipment.
Eye screenings of people with diabetes in underserved communities revealed that one in five had early stage diabetic retinopathy, according to a new study by a research consortium including investigators at the University of Alabama at Birmingham.
A technique developed by astronomers seeking a clear view of distant objects in space is being intensively studied as a new approach to measuring and correcting visual abnormalities.
Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director for basic sciences at UC San Diego Moores Cancer Center, was named today as one of seven recipients of the Ant-nio Champalimaud Vision Award in Lisbon, Portugal.
Research by Keck Medicine of USC ophthalmology scientists demonstrates that African Americans bear heavier burden of diabetic macular edema (DME), one of the leading causes of blindness in diabetic patients in the United States.
ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.
Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry.
Despite recent advances in prevention and treatment of most vision loss attributed to diabetes, a new study shows that fewer than half of Americans with damage to their eyes from diabetes are aware of the link between the disease and visual impairment, and only six in 10 had their eyes fully examined in the year leading up to the study.